Publication of a Transparency Notification Received by Mithra Pharmaceuticals sa/nv


Mithra Pharmaceuticals SA/NV (Euronext Brussels: MITRA) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from OGEO Fund OFP and from OGESIP Invest SA, an investment company controlled by OGEO Fund.

OGEO Fund has notified Mithra that it has dropped below the 3% threshold on 21 November 2017 and now holds 0% of the 34,242,731 shares currently outstanding. According to the last transparency notification received by Mithra, OGEO Fund previously held 4.33% of outstanding shares (1,481,700 shares).

As a result of a transfer of shares from OGEO Fund to OGESIP Invest SA, OGESIP Invest SA now holds 3.45% of outstanding shares (1,181,700 shares), and hence crossed the reporting threshold of 3% on 21 November 2017.

The detailed transparency notifications are available on the Investors website of Mithra ( An updated overview of the Mithra’s large shareholdings will be included in the corporate governance charter of Mithra, which will be made available on its website.


Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO.

Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?